AICR awards $1.15 million for cancer prevention and survivorship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Seven researchers have received a total of $1.15 million from the American Institute for Cancer Research to study the relationship between diet, nutrition, physical activity, body weight and cancer prevention and survivorship.

The diverse research topics focus on cancers in women and men and identify a wide array of the most common risk factors and their impact on prevention, survivorship and recurrence.

The 2021 AICR research grantees are:

  • Christine Brainson, University of Kentucky Research Foundation: How dietary methionine influences lung cancer initiation and chemosensitivity,
  • Michael De Lisio, University of Ottawa: Aberrant myelopoiesis as a novel mechanism for the differential effects of obesity and exercise on colorectal cancer risk,
  • Brian Focht, Ohio State University: Addressing obesity to reduce cancer risk and health disparities in underserved populations,
  • Christopher Haiman, University of Southern California: Interactions of polygenic risk score with BMI, physical activity and dietary patterns on risk of breast, colorectal and prostate cancer in the Multiethnic Cohort,
  • Xin Lu, University of Notre Dame: Overcome resistance to cancer immunotherapy with ketogenic diet-induced epigenetic reprogramming,
  • Scherezade Mama, MD Anderson Cancer Center: Feasibility of an adapted multicomponent physical activity intervention to reduce psychosocial distress in rural adults following cancer diagnosis; and
  • Erik Nelson, University of Illinois at Urbana-Champaign: Determining the impact of different preparation techniques of foods high in cholesterol on breast cancer progression.

AICR has contributed more than $110 million to support over 750 studies conducted at universities, hospitals and research centers across North, South and Central America.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login